KRAS and colorectal carcinoma: Patients initially respond well to these treatments but then often develop resistance.[4, 6, 7] In addition, 35% to 40% of patients with KRAS and NRAS gene mutations do not respond to targeted therapy.[5] CRC is a heterogeneous disease caused by a series of progressive histological changes, each of which is accompanied by specific genetic alterations.[8] There is an urgent need to elucidate the molecular mechanisms underlying CRC initiation and progression and identify new biomarkers and targets for the diagnosis and treatment of this disease.